Here are the 10-Q quarterly reports from Turn Therapeutics Inc. (TTRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TTRX filings page.
Turn Therapeutics Inc. (TTRX) reported a $6,230,868 net loss for the three months ended September 30, 2026, versus $1,904,184 a year earlier; nine-month net loss was $13,051,733 versus $3,473,150. It reported no revenue for the nine-month periods. Nine-month research and development expense was $1,189,697, compared with $230,636.
Cash and cash equivalents were $10,363,975 at September 30, 2026, and operating activities used $4,105,574 during the first nine months. The company estimates this cash can fund GX-03 development in atopic dermatitis and hidradenitis suppurativa into the third quarter of 2027, but says capital may not fund operations through at least the next 12 months, raising substantial doubt about its ability to continue as a going concern.
Phase 2b of GX-03’s atopic dermatitis study is enrolling 120-136 patients, with topline results expected in the first quarter of 2027; Phase 2a, with 50 patients, was completed in June 2026. In a subsequent event, the company issued a 15-trading-day draw-down notice on October 29, 2026, putting 272,642 shares to the investor at a $10.00 threshold price for a $2.7 million advance; the final amount and share count will be determined at the end of the draw-down period.
Turn Therapeutics Inc., a clinical-stage dermatology-focused biotech, reported a net loss of $6.8 million for the six months ended June 30, 2026, compared with $1.6 million a year earlier, driven by higher R&D spending, stock-based compensation and a sizable non-cash loss on derivatives.
Cash and cash equivalents rose to $10.3 million from $5.1 million at December 31, 2025, aided by a $7.0 million Avenue Capital term loan and collection of a $1.1 million subscription receivable. However, total liabilities increased to $16.3 million, including $6.1 million of derivative liability and $6.1 million of secured long-term debt, leaving stockholders’ equity at only $0.7 million.
The company disclosed an accumulated deficit of $29.2 million and stated that expected cash needs raise substantial doubt about its ability to continue as a going concern, despite estimating its current cash can fund GX‑03 development in atopic dermatitis into the third quarter of 2027. Turn is advancing its lead topical candidate GX‑03 in an adaptive Phase 2 AD trial, expanding enrollment after an interim analysis with no major safety concerns, and is preparing additional programs in onychomycosis and hidradenitis suppurativa while relying on future equity, debt and partnering to finance operations.
Turn Therapeutics reported a Q1 2026 net loss of $0.97 million, compared with $0.33 million a year earlier, as it ramps up development of its dermatology pipeline. Operating expenses rose to $1.25 million, mainly from higher public‑company costs and GX‑03 clinical spending.
Cash and cash equivalents increased to $11.22 million from $5.08 million at year-end, helped by a $7.0 million Avenue Capital term loan and receipt of prior share subscription proceeds. Management expects this cash to fund operations into the first quarter of 2027 but discloses substantial doubt about continuing as a going concern without significant additional financing.